Navigation Links
‘For-profit Dialysis Centers’ in the Spotlight Over Anti-anemia Drug Overdoe

A novel US study has exposed the key drivers behind the functioning of kidney dialysis profit centers across the United States. //Bottom line figures rule the roost, and these centers prescribe overdoses of anti-anemia drugs to realize higher hemoglobin levels in the patients.

The study which is published in the Journal of the American Medical Association, demonstrates how over dosing patients with anti-anemia drugs could endanger their lives. Abnormally high hemoglobin increases the risk of heart attacks, strokes and blood clots.

Healthy kidneys secrete a hormone called erythropoietin which is the catalyst behind the production of red blood cells in the bone marrow. Those patients suffering kidney disease do not produce adequate erythropoietin, therefore there is a dearth of red blood cells, causing anemia.

Epoetin is a drug that acts as a substitute for erythropoietin, and is being prescribed to kidney patients during the course of dialysis. The dosage is altered depending upon their hemoglobin levels and how anemic they are.

Hospitals as well as independently owned profit based units of dialysis across the United States are known to claim reimbursement from the government insurance scheme, Medicare, for the treatment meted out to the patient, which also includes the anti anemia drug epoetin.

According to this study conducted, Epoetin therapy accounted for 1.8 billion dollars of medical drug expenditure in 2004.

The records of 159,522 adult Medicare-eligible, end-stage renal disease patients from the US Renal Data System, undergoing hemodialysis at various centers during November and December 2004 was analyzed using statistical regression models to understand the average epoetin dose and dose adjustments executed by the profit centers. The findings revealed that dosing of the drug epoetin fluctuated according to the status of the dialysis centers, whether they were profit or non-profit center s.

It was also observed that the 106,116 patients who availed treatment from the large for-profit dialysis centers were regularly given the highest doses of epoetin as against 28,199 patients who undertook treatment from nonprofit centers, irrespective of their level of anemia.

It was also observed that a hospital-based centre administered an average dose of 16,188 units per week of epoetin, as against ‘for-profit chain centers’ that administered an average dose of 20,838 units a week. The researchers inferred, "Dialysis facility organizational status and ownership are associated with variation in epoetin dosing in the United States. Different epoetin dosing patterns suggest that large for-profit chain facilities used larger dose adjustments and targeted higher hematocrit levels."

This trend has prompted the FDA to issue warnings for Epoetin against the indiscriminate use of this drug.

Related medicine news :

1. Easier Dialysis for Kids
2. More Patients Going In For Home Dialysis
3. Dialysis Clinics Owned By Fresenius Flourishes Due To Its Customers
4. SRN Hospital Dialysis Unit To Resume Function
5. Heparin Based Nanoscale Materials Developed For Dialysis Treatment
6. Exercise Combined with Dialysis Yields Better Results
7. Vitamin E-Coated Dialysis Filters Help Fight Anemia in Hemodialysis Patients
8. Dialysis Patients With Metabolic Syndrome Show Increased Risk for Heart Disease
9. Dialysis Trust Set Up in Bangalore by End-stage Kidney Patients
10. Childhood Obesity Vs Malnutrition- A Spotlight On WHO Obesity Measurement For Kids
11. Spotlight on Aids-prevention
Post Your Comments:

(Date:11/25/2015)... ... November 25, 2015 , ... Privately ... has undertaken significant expansion of its current state of the art research, development ... PharmaTech’s strategy to increase its manufacturing capacity as well as to support its ...
(Date:11/25/2015)... ... November 25, 2015 , ... Many people know of the ... gain, cold hands, and dry skin. But many people who find their cholesterol levels ... regimen instead of their thyroid, especially if they don’t have any of the other ...
(Date:11/25/2015)... ... November 25, 2015 , ... ... on providing comprehensive solutions involving adult stem cell therapies to patients with chronic ... the “Regenestem” name as a Registered Trademark (RTM). , Organizations are required to ...
(Date:11/25/2015)... ... November 25, 2015 , ... ... prices in an early celebration of the early holiday shopping season. Starting Wednesday ... each (normally $33.95 ea). Black Friday promotional pricing is in addition to any ...
(Date:11/24/2015)... ... November 24, 2015 , ... Eric C. ... the many benefits of the revolutionary BIOLASE WaterLase iPlus 2.0™ system. This advanced ... traditionally used by a dentist in Gettysburg, PA . From routine visits ...
Breaking Medicine News(10 mins):
(Date:11/25/2015)... announced the issue of United States patent No. 9,192,509  entitled: " Methods ... the company,s AVACEN 100 dry heat therapy medical device and specific methods of use, referred to ... Photo - ... ... ...
(Date:11/25/2015)... , Nov. 25, 2015 USP ... hazardous drug preparations (e.g. pharmacists, pharmacy technicians, nurses, ... veterinary technicians). The chapter also covers all entities ... (e.g., pharmacies, hospitals, other healthcare institutions, patient treatment ... --> --> What ...
(Date:11/25/2015)... Nov. 25, 2015  Mindray Medical ... MR ), a leading developer, ... worldwide, today announced that it will ... of shareholders at the Company,s Hong Kong office ... Prince Edward West Road, Mongkok KL, Hong ...
Breaking Medicine Technology: